References

Filters: Author is T M Welzel  [Clear All Filters]
W
Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65(11):1861-1870.
Welzel TM, Zeuzem S, Dumas EO, et al. GARNET: High SVR rates following eight-week treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir for patients with HCV genotype 1b infection [Abstract 163]. In: New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016. New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, September 23-24, 2016. Paris; 2016.
Welzel TM, Zeuzem S, Petersen J, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program [Abstract 37]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 13-17. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 13-17. San Francisco, CA; 2016.
Top